Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 10Hodgkin Disease 5Lymphoma 3Sarcoma 2Thyroid Neoplasms 1Recurrence 1Neoplasm Metastasis 1Leiomyosarcoma 1Carcinoma, Medullary 1

Interventions

Sorafenib 3vandetanib 2alectinib 2Sodium 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Bevacizumab 2tremelimumab 1temsirolimus 1ponatinib 1perflutren 1pembrolizumab 1methyl N-acetylsibirosaminide 1lenvatinib 1gallium 68 PSMA-11 1fosbretabulin 1durvalumab 1combretastatin 1cobimetinib 1cabozantinib 1X-Rays 1Valproic Acid 1Thyroxine 1Technetium Tc 99m Sestamibi 1Sirolimus 1Radiofrequency Ablation 1Presenilin-1 1Paclitaxel 1PLX8394 1Lubricant Eye Drops 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thyroid Neoplasms × Dacarbazine × Clear all
NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡